In this interview with Outsourced Pharma, Anixa Biosciences’s CEO, Amit Kumar, PhD, shares why Cytovance was the right CDMO partner, with the microbial expertise, proven commercial execution, and long-term partnership mindset needed to advance the company’s breast cancer vaccine through the next phases of development.
Outsourcing Everything Is The Biotech Blueprint Read More »
Anixa Biosciences has selected Cytovance Biologics for Phase 2 Manufacturing of Breast Cancer Vaccine.
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and mammalian capabilities, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones. View the video below to hear from Thomas O. Kohl, PhD, our Senior Director of Business Development, on the agility and experience
Outsourced Pharma Capacity Update – July 2025 Read More »
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and mammalian capabilities, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones. View the video below to hear from Stijn Cattaert, Director of Business Development, on the agility and experience that make Team Cytovance the ideal
Outsourced Pharma Capacity Update – April 2025 Read More »
New year, new programs! Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones in 2025 and beyond. View the video below to hear from Rose Rhomberg, Senior Business Development Director, about our 20+
Outsourced Pharma Capacity Update – January 2025 Read More »
This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of product requirements. OKLAHOMA CITY, Oklahoma, TORRANCE, California, January 13, 2025 – In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones in 2024 and beyond. View the video below to hear from Rose Rhomberg, Senior Business Development Director, about our 20+ years of experience and
Outsourced Pharma Capacity Update – October 2024 Read More »
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones in 2024 and beyond. View the video below to hear from Axel Schleyer, CCO, and Brent Van Rite, Sr. Director of Manufacturing, about our
Outsourced Pharma Capacity Update – July 2024 Read More »
This partnership provides the industry with an integrated solution for customers seeking to outsource cell line development through to cGMP manufacturing of their mammalian-expressed products leveraging the latest available technologies. OKLAHOMA CITY, Oklahoma, UNION CITY, California, July 30, 2024 – To better support the rising demand for development and manufacturing of more complex biologics particularly
This partnership provides the industry with cutting-edge options for mammalian-expressed products. OKLAHOMA CITY, Oklahoma, MONTHEY, Switzerland, May 8, 2024 – ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based
